A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings

被引:7
|
作者
Miyasaka, Tomomitsu
Aoyagi, Tetsuji [2 ]
Uchiyama, Binei [3 ]
Oishi, Kazunori [4 ]
Nakayama, Toshinori [5 ]
Kinjo, Yuki [6 ]
Miyazaki, Yoshitsugu [6 ]
Kunishima, Hiroyuki [2 ]
Hirakata, Yoichi [2 ]
Kaku, Mitsuo [2 ]
Kawakami, Kazuyoshi [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Med Microbiol Mycol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Sendai, Miyagi 9808575, Japan
[3] Katta Gen Hosp, Div Resp Dis, Shiroishi, Miyagi, Japan
[4] Osaka Univ, Microbial Dis Res Inst, Dept Special Pathogens, Lab Clin Res Infect Dis, Suita, Osaka 565, Japan
[5] Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba, Japan
[6] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Tokyo, Japan
关键词
Pneumococcal polysaccharide vaccine; Antibody production; NKT cells; CD1D-RESTRICTED NKT CELLS; STREPTOCOCCUS-PNEUMONIAE; PANDEMIC INFLUENZA; BACTEREMIA; ACTIVATION; INDUCTION; ANTIGENS; ANTIBODY; SUBSETS; MODEL;
D O I
10.1016/j.vaccine.2012.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal polysaccharide vaccine (PPV), a type-2 thymus-independent antigen, induces the activation of B cells by directly triggering their antigen receptors. Although this type of antigen generally does not undergo class switching from IgM to IgG, PPV has been known to induce IgG2 in vaccinated subjects, which suggests the possible involvement of certain innate immune lymphocytes supporting the activation of B cells and their class switching. In the present study, we addressed the possibility that natural killer (NK) T cells are involved in Ab production caused by PPV. We measured serum levels of IgG against pneumococcal capsular polysaccharides and the numbers of CD4(+), CD8(+) and CD4(-)CD8(-) double negative (ON) invariant NKT (iNKT) cells and CD3(+)CD56(+) NKT cells in the peripheral blood before and after PPV injection. IgG was increased after PPV injection, peaking at 4 weeks after injection in serotypes 6B, 19F and 23F and at 3 months in serotype 14. Low responders, whose serum concentrations of IgG peaked at less than double their original levels, constituted 16%, 13%, 13% and 16% of vaccinated subjects with regard to serotypes 613, 14, 19F and 23F, respectively. A significant positive correlation was detected between an increase in ON iNKT cells and the elevation of anti-serotype 14 IgG; in serotype 19F, DN iNKT cells were more markedly increased in responders than in low responders. These results suggest that DN iNKT cells may be involved in IgG production caused by vaccination against pneumococcal capsular polysaccharides. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3304 / 3310
页数:7
相关论文
共 50 条
  • [21] Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
    Haggenburg, Sabine
    Garrido, Hannah M. Garcia
    Kant, Iris M. J.
    van der Straaten, Hanneke M.
    De Boer, Fransien
    Kersting, Sabina
    Issa, Djamila
    Te Raa, Doreen
    Visser, Hein P. J.
    Kater, Arnon P.
    Goorhuis, Abraham
    De Heer, Koen
    VACCINES, 2023, 11 (07)
  • [22] Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes
    Ciprero, Karen L.
    Marchese, Rocio D.
    Richard, Patrick
    Baudin, Martine
    Sterling, Tina M.
    Manoff, Susan B.
    Radley, David
    Stek, Jon E.
    Soubeyrand, Benoit
    Grabenstein, John D.
    Samson, Sandrine I.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2135 - 2141
  • [23] In Vitro Immunogenic and Immunostimulatory Effects of Zwitterionized 23-Valent Pneumococcal Polysaccharide Vaccine Compared With Nonzwitterionized Vaccine
    Abdulamir, Ahmed S.
    Hafidh, Rand R.
    Abubaker, Fatimah
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2010, 71 (01): : 60 - 77
  • [24] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Cornelius Remschmidt
    Thomas Harder
    Ole Wichmann
    Christian Bogdan
    Gerhard Falkenhorst
    BMC Infectious Diseases, 16
  • [25] Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy
    Garrido, Hannah M. Garcia
    Schnyder, Jenny L.
    Haydari, Beheshta
    Vollaard, Albert M.
    Tanck, Michael W. T.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)
  • [26] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [27] Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy
    Lu, Ching-Lan
    Hung, Chien-Ching
    Chuang, Yu-Chung
    Liu, Wen-Chun
    Su, Chin-Ting
    Su, Yi-Ching
    Chang, Shu-Fang
    Chang, Sui-Yuan
    Chang, Shan-Chwen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (02) : 398 - 404
  • [28] Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
    Russell, F. M.
    Licciardi, P. V.
    Balloch, A.
    Biaukula, V.
    Tikoduadua, L.
    Carapetis, J. R.
    Nelson, J.
    Jenney, A. W. J.
    Waqatakirewa, L.
    Colquhoun, S.
    Cheung, Y. B.
    Tang, M. L. K.
    Mulholland, E. K.
    VACCINE, 2010, 28 (18) : 3086 - 3094
  • [29] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [30] Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
    Belmonti, Simone
    Rossetti, Barbara
    Modica, Sara
    Paglicci, Lorenzo
    Borghetti, Alberto
    Ciccullo, Arturo
    Picarelli, Chiara
    Cauda, Roberto
    De Luca, Andrea
    Montagnani, Francesca
    Lombardi, Francesca
    INFECTIOUS DISEASES AND THERAPY, 2019, 8 (03) : 453 - 462